T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2876
Holley
HLLY
$364M
| $143K | ﹤0.01% |
34,615
+4,767
| +16% | +$17.2K |
|
|
MPX
2877
DELISTED
Marine Products Corp
MPX
| $142K | ﹤0.01% |
16,155
| – | – |
|
2878
Perma-Fix Environmental Services
PESI
$380M
| $142K | ﹤0.01% |
+11,202
| New | +$143K |
|
2879
Spok Holdings
SPOK
$229M
| $142K | ﹤0.01% |
10,744
| – | – |
|
|
VOXR
2880
Vox Royalty Corp
VOXR
$371M
| $142K | ﹤0.01% |
29,938
+9,710
| +48% | +$44K |
|
2881
Critical Metals Corp
CRML
$974M
| $142K | ﹤0.01% |
20,399
+4,139
| +25% | +$45.1K |
|
2882
Paysafe
PSFE
$391M
| $140K | ﹤0.01% |
17,269
| – | – |
|
2883
Vivid Seats
SEAT
$82.8M
| $139K | ﹤0.01% |
+19,178
| New | +$189K |
|
|
FBLA
2884
FB Bancorp
FBLA
$253M
| $139K | ﹤0.01% |
+10,764
| New | +$134K |
|
2885
Viemed Healthcare
VMD
$356M
| $138K | ﹤0.01% |
18,564
| – | – |
|
2886
1-800-Flowers.com
FLWS
$263M
| $137K | ﹤0.01% |
34,649
+21,800
| +170% | +$85.6K |
|
2887
GoPro
GPRO
$119M
| $137K | ﹤0.01% |
96,763
| – | – |
|
2888
Granite Ridge Resources
GRNT
$658M
| $137K | ﹤0.01% |
28,937
| – | – |
|
2889
Lifecore Biomedical
LFCR
$180M
| $137K | ﹤0.01% |
16,646
+2,826
| +20% | +$20.9K |
|
|
LUCK
2890
Lucky Strike Entertainment
LUCK
$941M
| $137K | ﹤0.01% |
+16,149
| New | +$140K |
|
|
STLN
2891
Starling Oncology, Inc. Common Stock
STLN
$644M
| $136K | ﹤0.01% |
38,002
+8,238
| +28% | +$30.6K |
|
2892
New Fortress Energy
NFE
$93M
| $135K | ﹤0.01% |
118,292
| – | – |
|
|
QVCGA
2893
DELISTED
QVC Group Inc Series A
QVCGA
| $133K | ﹤0.01% |
+12,629
| New | +$137K |
|
|
FRMI
2894
Fermi Inc
FRMI
$4.33B
| $133K | ﹤0.01% |
+16,516
| New | +$322K |
|
2895
Intellicheck
IDN
$75.1M
| $131K | ﹤0.01% |
19,500
| – | – |
|
|
NEXN
2896
Nexxen International
NEXN
$586M
| $131K | ﹤0.01% |
19,939
| – | – |
|
2897
AlTi Global
ALTI
$465M
| $130K | ﹤0.01% |
27,873
+6,197
| +29% | +$25.6K |
|
|
CTNM
2898
Contineum Therapeutics
CTNM
$597M
| $130K | ﹤0.01% |
+11,300
| New | +$129K |
|
2899
The Honest Company
HNST
$545M
| $129K | ﹤0.01% |
49,636
| – | – |
|
2900
Abeona Therapeutics
ABEO
$364M
| $128K | ﹤0.01% |
24,127
+969
| +4% | +$4.88K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.